Drugs / Licensed influenza vaccine
Trials 0
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03390166 Comparator | Jul 2017 → Mar 2018 | influenza | Mahidol University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06694389 Comparator | Nov 2024 → Nov 2025 | COVID-19, influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06178991 Comparator | Dec 2023 → Nov 2024 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
| Phase 3 | NCT04548518 Comparator | Aug 2020 → Jun 2023 | influenza | Mahidol University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Licensed influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03390166 ↗ |
| Modality | Vaccine | “seasonal trivalent split, inactivated influenza vaccine” NCT03390166 ↗ |
| Route | Intramuscular | “The comparator licensed influenza vaccine will be administered via the intramuscular route” NCT03390166 ↗ |